Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

Morgans AK, Pieczonka CM, Yu EYW, Nagar H, Gomella LG, Osman MM, Koo PJ, Finkelstein SE

Open source

DOI
10.7150/thno.132930
Published
2026
Container
Theranostics
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7150/thno.132930,
  title = {Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).},
  author = {Morgans AK and Pieczonka CM and Yu EYW and Nagar H and Gomella LG and Osman MM and Koo PJ and Finkelstein SE},
  year = {2026},
  journal = {Theranostics},
  doi = {10.7150/thno.132930},
  url = {https://doi.org/10.7150/thno.132930}
}

RIS

TY  - JOUR
TI  - Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).
AU  - Morgans AK
AU  - Pieczonka CM
AU  - Yu EYW
AU  - Nagar H
AU  - Gomella LG
AU  - Osman MM
AU  - Koo PJ
AU  - Finkelstein SE
PY  - 2026
JO  - Theranostics
DO  - 10.7150/thno.132930
UR  - https://doi.org/10.7150/thno.132930
ER  - 

APA

AK, M., CM, P., EYW, Y., H, N., LG, G., MM, O., PJ, K., & SE, F. (2026). Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).. Theranostics. https://doi.org/10.7150/thno.132930

Source records